= 89-57-6 反应条件:1.1 Reagents: Sodium Hydroxide,Hydrogen Catalysts: Palladium Solvents: Methanol,Water; 50 °C1.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 4.1 - 4.2,Rt 标题:Process For Amination Via Azo Coupling Of Non-Toxic Aromatic Amines With Organic Compounds Followed By Cat. Hydrogenation 参考文献:Italy]
54234-73-0 = 89-57-6 反应条件:1.1 Reagents: Potassium Hydroxide,Hydrogen Catalysts: Nickel Solvents: Water1.2 Reagents: Hydrochloric Acid Solvents: Water 标题:Reduction Of 5-Nitrosalicylic Acid In Water To Give 5-Amino-Salicylic Acid 作者:Breviglieri,Gabriele; Giacomo,Bruno; Sergio,Contrini; Cinzia,Assanelli; Campanab,Eileen; Et Al 参考文献:Molecules [online Computer File] 日期:2001 卷标:6(12)]
96-97-9 = 89-57-6 反应条件:1.1 Reagents: Zinc,Hydrochloric Acid Solvents: Water; Cooled; 4 H,Reflux 标题:Computational And Synthetic Approaches For Developing Lavendustin B Derivatives As Allosteric Inhibitors Of Hiv-1 Integrase 作者:Agharbaoui,Fatima E.; Hoyte,Ashley C.; Ferro,Stefania; Gitto,Rosaria; Buemi,Maria Rosa; Et Al 参考文献:European Journal Of Medicinal Chemistry 日期:2016 卷标:123 页码:673-683
专利号:US-8546532-B2 优先权日:2008-04-17 标题:Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders 发明人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS 权利人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS; DECLION PHARMACEUTICALS INC 摘要:The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.
专利号:US-10005720-B2 优先权日:2013-04-05 标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same 发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L 权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL 摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.
专利号:US-2025206743-A1 优先权日:2022-03-25 标 题:Tyk2 inhibitor synthesis and intermediates thereof 发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG 权利人:TAKEDA PHARMACEUTICALS CO 摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.
专利号:US-6376475-B1 优先权日:1997-05-30 标 题 :Control of immune responses by modulating activity of glycosyltransferases 发明人:MARTH JAMEY D; PAULSON JAMES C 权利人:ABARON BIOSCIENCES INC; UNIV CALIFORNIA 摘要:The invention provides methods for inhibiting immune responses by inhibiting the biosynthesis of the sialyl galactosides that are involved in immune responses. In particular, B lymphocyte-mediated immune responses are mediated by interfering with synthesis of α2,6 sialylgalactosides, while T lymphocyte-mediated immune responses are inhibited by blocking synthesis of α2,3 sialylgalactosides. The inhibition is accomplished by, for example, inhibiting the activity of a glycosyltransferase involved in synthesis of the respective sialyl galactoside.
专利号:US-2008287407-A1 优先权日:2003-12-10 标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use 发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI 权利人:NITROMED INC 摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.
专利号:US-8304409-B2 优先权日:2002-07-03 标 题:Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use 发明人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI 权利人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI; NICOX SA 摘要:The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.
1: Rehman F, Rahim A, Airoldi C, Volpe PL. Preparation and characterization of glycidyl methacrylate organo bridges grafted mesoporous silica SBA-15 as ibuprofen and mesalamine carrier for controlled release. Mater Sci Eng C Mater Biol Appl. 2016 Feb;59:970-9. doi: 10.1016/j.msec.2015.11.005. Epub 2015 Nov 4. doi: 10.1016/j.ejpb.2015.09.002. Epub 2015 Sep 21. doi: 10.1016/j.msec.2015.05.031. Epub 2015 May 10. doi: 10.1097/MIB.0000000000000562. doi: 10.1097/MIB.0000000000000540. Review. doi: 10.1016/j.ijpharm.2015.06.026. Epub 2015 Jun 23. pii: bcr2015210689. doi: 10.1136/bcr-2015-210689. doi: 10.1007/s10620-015-3866-7. Epub 2015 Nov 12. 9: Tenjarla S. Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels. Drugs R D. 2015 Jun;15(2):211-5. doi: 10.1007/s40268-015-0097-5. 10: Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D, Kaimakliotis I, Eliakim R, Ng SC, Ben-Horin S. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1444-9.e1. doi: 10.1016/j.cgh.2015.02.019. Epub 2015 Feb 24. doi: 10.1080/00325481.2016.1152876. Epub 2016 Mar 1. doi: 10.3748/wjg.v21.i27.8366.
合成参考文献
参考文献:10.1002/ibd.21222 摘要:Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T, Stagg AJ, Knight SC. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis. 2010 Aug;16(8):1286–98. doi: 10.1002/ibd.21222. 参考文献:10.2147/ceg.s17634 摘要:Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gastroenterol. 2011;4():55–73. 参考文献:10.2147/ceg.s18381 摘要:Dorofeyev AE, Kiriyan EA, Vasilenko IV, Rassokhina OA, Elin AF. Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. Clin Exp Gastroenterol. 2011;4():141–53. 参考文献:10.1002/ibd.21819 摘要:Kevans D, Greene J, Galvin L, Morgan R, Murray FE. Mesalazine-induced bronchiolitis obliterans organizing pneumonia (BOOP) in a patient with ulcerative colitis and primary sclerosing cholangitis. Inflamm Bowel Dis. 2011 Oct;17(10):E137–8. doi: 10.1002/ibd.21819. 参考文献:10.1021/pr2003598 摘要:Le Gall G, Noor SO, Ridgway K, Scovell L, Jamieson C, Johnson IT, Colquhoun IJ, Kemsley EK, Narbad A. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res. 2011 Sep 02;10(9):4208–18. doi: 10.1021/pr2003598.